Long noncoding RNAs in Right Ventricular Heart Failure towards personalized healthcare

Project Details


Cardiovascular diseases have a high socio-economic burden, among which heart failure plays a major role. Both left ventricular heart failure (LVHF) and pulmonary arterial hypertension (PAH) trigger initially right ventricular hypertrophy (RVH) and eventually right ventricular heart failure (RVHF). RVHF worsens prognosis of patients and remains a poorly preventable disease, partly due to a limited knowledge of its mechanisms. In addition, there is a need for novel tools or biomarkers to predict or diagnose RVHF at an early stage of its evolution. To cope with these unresolved medical problems, we hypothesize that long noncoding RNAs (lncRNAs) are involved in the development of RVHF and constitute an unexplored reservoir of potential therapeutic targets and biomarkers. Therefore, our goal is to look into the molecular mechanisms responsible for the development of RVHF, focusing on lncRNAs. Specifically, the project will address the following research questions:
• Are lncRNAs regulated in RVHF?
• Do they functionally impact RVHF development?
• What are the mechanisms involved?
• Can lncRNAs be used to prevent or treat RVHF?
• Can lncRNAs help clinicians in patient monitoring and risk stratification?
The proposed project is patient-centered and has multiple expected impacts. First, a scientific impact through an enhanced knowledge of the functional role and biomarker potential of lncRNAs in RVHF, possibly triggering the development of novel clinical options for patient’s management. LncRNA-based identification of patients at high risk of developing RVHF would allow more frequent monitoring, treatment intensification or modification, with the goal of avoiding, delaying or alleviating RVHF. Hence, the project may contribute to reduce the burden of RVHF, thereby impacting the socio-economic burden of the disease. By suggesting novel treatments based on lncRNAs, the project may also impact patient outcomes via personalized healthcare.
The project is bilateral between clinical (Narodowy Instytut Kardiologii [NIK] and Europejskie Centrum Zdrowia [ECZ]) and translational research centers (CMKP) in Warsaw, Poland, and Luxembourg (Luxembourg Institute of Health, LIH).
Effective start/end date1/01/2431/03/28


  • FNR - Fonds National de la Recherche: €531,000.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.